PCV10 Reactogenicity and Immunogenicity Study - Malindi

PHASE4UnknownINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2018

Conditions
Pneumococcal Pneumonia
Interventions
BIOLOGICAL

PCV10 and DTaP

A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.

BIOLOGICAL

PCV10 and DTaP

A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.

BIOLOGICAL

hepatitis A vaccine, DTaP, PCV10

A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.

Trial Locations (1)

Unknown

Malindi District Hospital, Malindi

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Kenya Ministry of Health

OTHER_GOV

collaborator

University of Oxford

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

KEMRI-Wellcome Trust Collaborative Research Program

OTHER